The iron-chelating potential of silybin in patients with hereditary haemochromatosis

European Journal of Clinical Nutrition

Volumn 64, Issue 10, 2010, Pages 1239-1241

  Hutchinson, C ^a,b   Bomford, A ^a   Geissler, C A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

Author keywords

hereditary haemochromatosis; iron absorption; milk thistle; silybin

Indexed keywords

ASCORBIC ACID; FERRITIN; HEMOGLOBIN; HFE PROTEIN; IRON; IRON CHELATING AGENT; LEGALON FORTE; SILIBININ; SILYMARIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; FEMALE; GENE MUTATION; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IRON ABSORPTION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HEMOSIDEROSIS; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TEA; VEGETARIAN DIET;

ADULT; AGED; CROSS-OVER STUDIES; FEMALE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTESTINAL ABSORPTION; IRON; IRON CHELATING AGENTS; IRON, DIETARY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; SILYMARIN;

SILYBUM MARIANUM;

EID: 77957829520     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2010.136     Document Type: Article

References (10)

1. Bares JM, Berger J, Nelson JE, Messner DJ, Schildt S, Standish LJ et al. (2008). Silybin treatment is associated with reductionin serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol 42, 937-944.
2. Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S et al. (2001). Silybin, a new iron-chelating agent. J Inorg Biochem 85, 123-129.
3. Conway RE, Geissler CA, Hider RC, Thompson RPH, Powell JJ (2006). Measurement of dietary iron bioavailability using serum iron curves. J Nutr 136, 1910-1914.
4. Cook JD, Monsen ER (1977). Vitamin C, the common cold and iron absorption. Am J Clin Nutr 30, 235-241.
5. Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M et al. (2009). Combined therapy of silymarin and desferrioxamine in patients with ß-thalassaemia major: a randomised double-blind clinical trial. Fundam Clin Pharmacol 23, 359-365.
6. Holland B, Welch AA, Unwin ID, Buss DH, Paul AA, Southgate DAT (1991). McCance and Widdowson's the Composition of Foods, 5th edn. The Royal Society of Chemistry and Ministry of Agriculture, Fisheries and Foods: London p 462.
7. Hoppe M, Hulthen L, Hallberg L (2004). The validation of using serum iron increase to measure iron absorption in human subjects. Br J Nutr 92, 485-488.
8. Hurrell RF, Reddy M, Cook JD (1999). Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr 81, 289-295.
9. Hutchinson C, Geissler CA, Powell JJ, Bomford A (2007). Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56, 1291-1295.
10. Kaltwasser JP, Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C (1998). Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43, 699-704.